Singapore, April 29, 2008: Lupin Pharmaceuticals, , the wholly owned US subsidiary of Mumbai based Lupin Limited (Lupin), a leading Indian Pharmaceutical company has announced the launch of Suprax 400 mg Tablets (Cefixime USP) in the US. This line extension, further extends the brand franchise of Lupin’s flagship anti-infective Suprax (Cefixime for oral suspension 100 mg/ 5 ml and 200 mg/ 5ml)

 

Suprax 400 mg Tablets will help Lupin to further increase its share of the $450 million antibiotic market for the treatment of Urinary Tract Infections. It will also extend the use of Suprax to the patient population of children of the age of 12 years and above.

 

“Suprax 400 mg Tablets offers an additional value proposition to Pediatricians by covering the adolescent and teenage patient population. The incidence of Urinary Tract Infections is high in children and Pediatricians are the 5^th largest specialty prescribing antibiotics for this indication. We expect Suprax 400 mg Tablets to add substantial value to the Suprax franchise” said, Dr Kamal Sharma, Managing Director, Lupin.

 

Suprax 400 mg Tablets will be promoted by a 60 strong specialty pediatric sales force. Lupin is also evaluating additional options of reaching out to other specialty doctors. It’s efforts will be supplemented by innovative promotional campaigns.

 

The Suprax brand basket now includes, Suprax (Cefixime for oral suspension 100 mg/ 5 ml and 200 mg/ 5ml and Suprax 400 mg tablets.